Migersi Medical Secures RMB 12 Million in Series Angel Funding Led by Northern Light Venture Capital to Advance Ophthalmic Minimally Invasive Devices

Recently, MIGERSI announced the completion of an angel round of financing worth 12 million yuan. This round was led by Northern Light Venture Capital, with follow-up investment from Zhonglu International, a seed round shareholder. The proceeds will mainly be used for team building and various tasks before registration and inspection.

Previously, MIGERSI completed a seed funding round of several million yuan in June 2021. Within less than a year, MIGERSI has successively completed two rounds of financing, which not only reflects the strong foundational capabilities of its core team but also fully demonstrates investors' favor towards the ophthalmic minimally invasive device sector and MIGERSI.

It is reported that MIGERSI, founded in 2021, is an innovative medical device company focusing on minimally invasive ophthalmology, with its source technology being active cationic polymer biomaterials. The company's investment entity is located in Chongqing, while its operational base is situated in Chengdu Tianfu International Bio City. It closely follows the trend of integrated development in the Sichuan-Chongqing region and leverages the coordinated resources of both areas to accelerate corporate growth.

Since its establishment, MIGERSI has developed two major business directions: a materials technology platform and the research and development of ophthalmic minimally invasive devices. The materials technology platform, which synthesizes the SIBS material system through cationic polymerization technology, has now established stable, mass-production equipment in collaboration with the Biomedical Materials and Innovation Center at Chengdu Tianfu International Bio City, and is currently undergoing ISO13485 system certification.

In the research and development of ophthalmic minimally invasive instruments, the first product launched by MIGERSI is a glaucoma minimally invasive surgical instrument. After the GMP facility is in place and process and sterilization validations are completed, it will enter the registration inspection phase. In addition to the field of glaucoma, ICL lenses in the field of optometry will also be another key focus for MIGERSI.

In terms of the team, Li Jiwei, the founder of MIGERSI, has a background in materials science from the Chinese Academy of Sciences and more than ten years of experience in market sales, investment, and mergers and acquisitions in both foreign enterprises and domestically listed Growth Enterprise Market companies. The other founding team members have accumulated years of experience in the field of minimally invasive ophthalmology, with solid expertise in market agency sales, conceptual design, prototype validation, and a systematic understanding of processing techniques.

With the widespread application and development of minimally invasive surgery today, the market scale corresponding to ophthalmic minimally invasive instruments is continuously expanding. Next, MIGERSI will take this financing as an opportunity, under the strong support of the Biotechnology Bureau of Chengdu High-Tech Zone and Tianfu International Bio City, to quickly complete the implementation of the GMP facility and push the product into the registration inspection phase as soon as possible. Meanwhile, MIGERSI is also strengthening team building, initiating the development of more product lines, and advancing research and development in material and technology lines.

Fang Yu, Partner of Northern Light Venture CapitalIn recent years, the ophthalmology industry has developed rapidly. Although glaucoma is the world's leading irreversible blinding eye disease, there have been few breakthroughs in either drug or device treatments. MIGS (Minimally Invasive Glaucoma Surgery) is gradually becoming a mainstream treatment due to its minimal invasiveness, high safety, and fewer complications. The MIGERSI team has unique expertise in cationic polymerization biomaterial technology, and future application scenarios based on material science advancements could extend to anti-scarring membranes, ICL, and other fields. Northern Light Venture Capital is optimistic about the company’s future development and is delighted to cooperate at an early stage. We look forward to MIGERSI continuing to make strides, benefiting patients, and hope this project will help uncover more partners in the Sichuan-Chongqing region.

China Continental InternationalRepresentative stated: "The MIGERSI team has been diligently working in the细分赛道 of ophthalmic glaucoma, leveraging its advantages in material technology within MIGS minimally invasive surgery to develop and establish solutions that meet market demands. Zhonglu International Group fully participated in the investment of MIGERSI's seed round and angel round financing, as we continue to have strong confidence in the company’s future potential in the field of ophthalmic minimally invasive surgery and new materials. We are honored to collaborate with MIGERSI and witness the company's growth, and we look forward to MIGERSI developing more new product lines in the future."

Northern Light Venture Capital (NLVC), founded by Mr. Feng Deng in 2005, is a venture capital firm dedicated to "building world-class Chinese entrepreneurs and nurturing world-class Chinese enterprises." It currently manages six USD funds and four RMB funds, with assets under management exceeding 30 billion yuan. NLVC focuses on investing in early-stage, technology-driven outstanding companies and has invested in more than 400 excellent enterprises across new technologies, healthcare, and new consumer sectors.

Northern Light Venture Capital entered the healthcare sector in 2009. Over the past decade, Northern Light has invested in various subfields including innovative drugs + biotechnology, medical devices + IVD + Lifescience, digital healthcare, and new medical services, covering almost the entire industry chain. It has successively invested in more than 90 healthcare innovation enterprises such as CITIC Pharmaceuticals, BGI, Burning Rock Biotech, Zelgen Biopharmaceuticals, iRay Technology, Connect Biopharma, Cytek Biosciences, Guoke Hengtai, Taimei Medical, Belief BioMed, Yidao Bio, Oriental Startalk, and Cadyotech, committing to promote technological development and social progress while moving forward hand in hand with entrepreneurs.

China Land International Group Limited is a comprehensive investment holding company, established in 2005, with businesses covering international trade, mining development, construction machinery sales, and equity investment.